AccessClosure, Inc. – Trademark Portfolio

Entity Type: 03

AccessClosure, Inc. holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 12 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include MYNXGRIP, MYNX CONTROL, and GRIP TECHNOLOGY. The owner is based in Mountain View, CA.

645 Clyde Avenue

Mountain View, CA 94043

13 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

AccessClosure, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (12 filings)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does AccessClosure, Inc. have?

AccessClosure, Inc. has 13 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 abandoned, 8 cancelled.

What trademark classes does AccessClosure, Inc. file in?

AccessClosure, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are AccessClosure, Inc.'s most well-known trademarks?

AccessClosure, Inc.'s registered trademark portfolio includes well-known marks such as MYNXGRIP, MYNX CONTROL, and GRIP TECHNOLOGY. These are among 3 currently registered trademarks in the portfolio.

What is AccessClosure, Inc.'s trademark registration success rate?

AccessClosure, Inc. has a 23% trademark registration rate, with 3 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.